News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Analysts have issued an average "Hold" rating for TriCo Bancshares (NASDAQ:TCBK), with a 12-month average price target of $56.60. The company exceeded quarterly earnings expectations with $1.06 EPS and $111.88 million in revenue. Institutional investors hold a significant stake, and TriCo Bancshares also offers …
Kaplan Fox & Kilsheimer LLP has announced a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) for investors who purchased securities between December 17, 2025, and July 26, 2026. The lawsuit alleges that Capricor made undisclosed changes to its statistical analysis plan for …
Capricor Therapeutics reported its 2026 quarterly results, showing a significant increase in revenue to $14.08M from $5.67M a year prior, alongside an increased net loss of ($40.73M) and a diluted loss per share of ($0.7). The company is progressing with its BLA for Deramiocel, …
Kessler Topaz Meltzer & Check, LLP announces a securities fraud class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR). Investors who purchased CAPR securities between December 17, 2025, and July 26, 2026, have until September 28, 2026, to seek lead plaintiff status. The lawsuit …
Canada Pension Plan Investment Board (CPP Investments) has filed an amended Schedule 13G/A, disclosing a 2.8% beneficial ownership stake in Americold Realty Trust, Inc. (COLD). This translates to 8,051,165 shares, over which CPP Investments holds sole voting and dispositive power. The filing indicates that …
Capricor Therapeutics (CAPR) stock surged by 97.39% following the publication of positive Phase 3 HOPE-3 trial data in The Lancet, showing its drug deramiocel slowed upper-limb decline in Duchenne muscular dystrophy. This scientific validation, coupled with an FDA Biologics License Application (BLA) under active …
Capricor Therapeutics (NASDAQ: CAPR) is facing a federal securities class action lawsuit alleging that the company made misleading statements regarding the regulatory prospects of its investigational cell therapy, deramiocel, for Duchenne muscular dystrophy. The lawsuit centers on alleged undisclosed changes to statistical analysis plans …
The Rosen Law Firm has announced a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) on behalf of investors who purchased securities between December 17, 2025, and July 26, 2026. The lawsuit alleges that Capricor made materially false and misleading statements regarding changes …
Earnings Call Insights: Capricor Therapeutics (CAPR) Q2 2026 MANAGEMENT VIEW * Linda Marbán (Co-Founder, President, CEO & Director) said the company’s Deramiocel BLA “remains under review with the FDA with a current PDUFA target action date of August 22,” and framed updates around “our …
This article provides a brief "Q2 Earnings Snapshot" for Capricor. The full content of the article is not available beyond the title, indicating it may be a placeholder or an article with minimal information.
Hagens Berman is encouraging investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) who suffered substantial losses to come forward regarding a securities fraud class action lawsuit. The lawsuit alleges that Capricor made false and misleading statements about the clinical trial data and regulatory pathway for …
Capricor Therapeutics reported a wider-than-expected Q2 2026 loss of $0.70 per share but saw its stock surge 83.6% after hours due to positive investor focus on its updated regulatory strategy for deramiocel, its Duchenne muscular dystrophy treatment. The company announced the FDA is open …
Capricor Therapeutics is facing a federal securities lawsuit alleging that the company failed to disclose crucial information regarding changes in the statistical analysis plan for Deramiocel, its lead therapy candidate. The lawsuit claims that these omissions, particularly concerning FDA interactions and data analysis, led …
Scotiabank has raised its price target for Americold Realty Trust (NYSE:COLD) from $15 to $16, maintaining a "sector perform" rating and indicating a potential upside of 5.43%. Despite this, the stock holds an average "Hold" rating from analysts with a consensus price target of …
Robbins Geller Rudman & Dowd LLP has announced a shareholder class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) for alleged violations of the Securities Exchange Act of 1934. Investors who purchased Capricor securities between December 17, 2025, and July 26, 2026, and suffered …
Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 8 a.m. ET CALL PARTICIPANTS Vice President, Investor Relations - Rich LelandChief Executive Officer - Rob ChambersChief Financial Officer - Chris Papa TAKEAWAYS Adjusted FFO per Share -- $0.35 for the second quarter, …
This article analyzes Trico Bancshares (NASDAQ: TCBK) using AI models, highlighting weak near-term sentiment but strong long-term potential. It identifies a mid-channel oscillation pattern and offers specific institutional trading strategies, including long, breakout, and short setups, with defined entry, target, and stop-loss levels. The …
Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ:CAPR) on behalf of investors who purchased securities between December 17, 2025, and July 26, 2026. The lawsuit alleges that Capricor made false and misleading statements and failed to …
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) on behalf of investors who purchased securities between December 17, 2025, and July 26, 2026. The lawsuit alleges that Capricor Therapeutics' shares collapsed after FDA briefing documents …
Search by ticker symbol or company name and select a result to open its chart.